We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

69 hedge funds and large institutions have $87.7M invested in Gyre Therapeutics in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 18 increasing their positions, 29 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,200% more call options, than puts

Call options by funds: $1.85M | Put options by funds: $43K

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.93% less ownership

Funds ownership: 9.54% → 8.61% (-0.93%)

22% less capital invested

Capital invested by funds: $113M → $87.7M (-$25.2M)

22% less funds holding

Funds holding: 89 → 69 (-20)

38% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 29

67% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 30

Holders
69
Holders Change
-20
Holders Change %
-22.47%
% of All Funds
1.2%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
10
Increased
18
Reduced
29
Closed
30
Calls
$1.85M
Puts
$43K
Net Calls
+$1.81M
Net Calls Change
-$539K

Top Buyers

1
2L
22NW LP
Washington
+$2.99M
2
SCM
Stonepine Capital Management
Oregon
+$2.87M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.05M
4
Millennium Management
Millennium Management
New York
+$1.14M
5
RC
RBF Capital
California
+$724K

Top Sellers

1
OM
Opaleye Management
Massachusetts
-$6.3M
2
BlackRock
BlackRock
New York
-$6.26M
3
State Street
State Street
Massachusetts
-$1.53M
4
ACP
Acuta Capital Partners
California
-$1.16M
5
Northern Trust
Northern Trust
Illinois
-$1.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
KM
51
Kalos Management
Georgia
$74K -$1.85K -54 -2%
SI
52
Stephens Inc
Arkansas
$73K +$30.3K +883 +65%
QSS
53
Quantitative Systematic Strategies
Florida
$70K -$62.8K -1,830 -46%
XT
54
XTX Topco
Cayman Islands
$66K +$69.8K +2,035 New
CCM
55
Colorado Capital Management
Colorado
$59K – – –
Charles Schwab
56
Charles Schwab
California
$57K -$300K -8,751 -83%
PP
57
PDT Partners
New York
$51K -$198K -5,760 -79%
SPIA
58
Steward Partners Investment Advisory
New York
$43K – – –
Group One Trading
59
Group One Trading
Illinois
$28K +$29.8K +868 New
CG
60
Cutler Group
California
$23K – – –
UBS Group
61
UBS Group
Switzerland
$11K -$24.8K -724 -68%
Royal Bank of Canada
62
Royal Bank of Canada
Ontario, Canada
$9K -$3.33K -97 -25%
FDCDDQ
63
Federation des caisses Desjardins du Quebec
Quebec, Canada
$4.87K – – –
CAGAS
64
Capital Advisory Group Advisory Services
Minnesota
$4K – – –
BNP Paribas Financial Markets
65
BNP Paribas Financial Markets
France
$2.13K -$54.4K -1,584 -96%
Wells Fargo
66
Wells Fargo
California
$2K -$255K -7,431 -99%
New York State Common Retirement Fund
67
New York State Common Retirement Fund
New York
$1K -$72K -2,099 -98%
JCM
68
Jacobi Capital Management
Pennsylvania
$1K – – –
QCG
69
Quadrant Capital Group
Ohio
$1K +$1.54K +45 New
OM
70
Opaleye Management
Massachusetts
– -$6.3M -166,667 Closed
N
71
Nuveen
North Carolina
– -$559K -14,777 Closed
ACM
72
Altium Capital Management
New York
– -$453K -11,991 Closed
Russell Investments Group
73
Russell Investments Group
United Kingdom
– -$269K -7,129 Closed
Ameriprise
74
Ameriprise
Minnesota
– -$244K -6,451 Closed
California State Teachers Retirement System (CalSTRS)
75
California State Teachers Retirement System (CalSTRS)
California
– -$234K -6,189 Closed
1 2
3
4

GYRE Hedge Fund Activity: Q2 2021 in Review

69 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2021, worth a combined $87.7M — down 22% from $113M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of GYRE and 10 opened new positions — a net loss of 20 holders — while 29 trimmed existing stakes and 18 added.

The largest buyer was 22NW LP, adding an estimated $2.99M. The largest seller was Opaleye Management, exiting entirely with an estimated $6.3M sold.

  • 69 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2021, down from 89 in Q1 2021.
  • Funds reported $87.7M of Gyre Therapeutics stock for Q2 2021, down 22% quarter-over-quarter.
  • 10 funds opened new Gyre Therapeutics positions in Q2 2021 and 30 closed out, a net change of -20 holders.
  • The largest Gyre Therapeutics buyer in Q2 2021 was 22NW LP, an estimated $2.99M added.
  • The largest Gyre Therapeutics seller in Q2 2021 was Opaleye Management, an estimated $6.3M sold.

Based on aggregated 13F filings for Q2 2021.